Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD)
Authors' conclusion
This study has identified by consensus a minimum dataset considered necessary to provide consistency and comparability in global studies of AGHD.
Study context
- Population
- Adults with GHD (AGHD); 17 clinical experts from 10 countries and two patient representatives (GloBE-Reg)
- Participants
- 6,732 adults35 studies
- Outcome
- Minimum dataset (MDS) for monitoring safety and effectiveness of GH in AGHD
Methodological detailsSystematic literature search in PubMed, Science Direct and Cochrane, Expert items graded independently on importance and ease of collection in routine clinical practice
- Systematic literature search in PubMed, Science Direct and Cochrane
- Expert items graded independently on importance and ease of collection in routine clinical practice
Recommendations
As reported in the abstract
Minimum dataset
Items provided by experts
190
Items achieving sufficient consensus and alignment with reported outcomes
86
45%
Final minimum dataset (MDS) items to be assessed
45
Final MDS items manually entered
43
Further findings
Outcome categories in included studies
- Cardiovascular
- 21 (60%) studies
- Serum IGF-I
- 13 (37%)
- IGF-I SDS
- 8 (23%)
- Adiposity measures
- 15 (44%)
- Psychosocial outcomes
- 10 (29%)
Age of participants in included studies
- Median age (range)
- 49 (range, 22-82) years
Original publication
Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD). Clin Endocrinol (Oxf). Published 21 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →